Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

31.68 -0.43 (-1.34%)
Streaming Delayed Price Updated: 10:27 AM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
5 Analysts Have This To Say About Legend Biotech
 
Via Benzinga
What Does the Market Think About Legend Biotech?
 
Via Benzinga
Demystifying Legend Biotech: Insights From 5 Analyst Reviews
 
Via Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Is Legend Biotech Gaining or Losing Market Support?
 
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
 
Via Benzinga
Where Legend Biotech Stands With Analysts
 
Via Benzinga
Earnings Scheduled For March 11, 2025
 
Via Benzinga
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Breaking Down Legend Biotech: 9 Analysts Share Their Views
 
Via Benzinga
(LEGN) - Analyzing Legend Biotech's Short Interest
 
Via Benzinga
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
 
Via Benzinga
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
 
Via Benzinga
9 Analysts Have This To Say About Legend Biotech
 
Via Benzinga
Where Legend Biotech Stands With Analysts
 
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
 
Via Benzinga
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
Newly created position to lead efforts focused on continued growth and sales 
From Legend Biotech USA Inc.
Via GlobeNewswire
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
 
Via Benzinga
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader 
From Legend Biotech USA Inc.
Via GlobeNewswire
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.